LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Elenco Azioni・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

181.15 -2.43

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

180.11

Massimo

184.98

Metriche Chiave
By Trading Economics
Entrata	262M -15M
Vendite	1.6M 996M
EPS	-0.3
Margine di Profitto	-1.486
Dipendenti	18,300
EBITDA	-11M 187M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+12.17% upside

Dividendi
By Dow Jones
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	267M 8.8B
Apertura precedente	183.58
Chiusura precedente	181.15

Notizie sul Sentiment di mercato

By Acuity

50%

155 / 344 Classifica in Healthcare

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 giu 2026, 19:20 UTC

I principali Market Mover

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 giu 2026, 21:27 UTC

Utili

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 20:20 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 giu 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 19:26 UTC

Discorsi di Mercato

Hog Futures Tumble to Close Week -- Market Talk

5 giu 2026, 19:10 UTC

Discorsi di Mercato

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 giu 2026, 19:03 UTC

Discorsi di Mercato

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 giu 2026, 18:59 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 giu 2026, 18:47 UTC

Discorsi di Mercato

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 giu 2026, 18:34 UTC

Discorsi di Mercato

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 giu 2026, 18:33 UTC

Acquisizioni, Fusioni, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 giu 2026, 17:50 UTC

Utili

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 giu 2026, 17:27 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 giu 2026, 16:48 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

5 giu 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

5 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

5 giu 2026, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 giu 2026, 15:26 UTC

Discorsi di Mercato

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 giu 2026, 15:25 UTC

Utili

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

5 giu 2026, 15:16 UTC

Discorsi di Mercato

Zcash Tumbles After Exploit Found -- Market Talk

5 giu 2026, 15:09 UTC

Discorsi di Mercato

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 giu 2026, 15:07 UTC

Discorsi di Mercato

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 giu 2026, 15:05 UTC

Discorsi di Mercato

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

12.17% in crescita

Previsioni per 12 mesi

Media 208.4 USD 12.17%

Alto 235 USD

Basso 160 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

155 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.